Gene therapy from the perspective of systems biology

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 5, 2010, Pages 570-577

  Gabhann, Feilim Mac ^a   Annex, Brian H ^b   Popel, Aleksander S ^c  

^a Johns Hopkins University   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACENTAL GROWTH FACTOR; PLASMID DNA; SMALL INTERFERING RNA;

ANGIOGENESIS; BIOINFORMATICS; GENE DOSAGE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; SYSTEMS BIOLOGY; TUMOR MICROENVIRONMENT;

CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; CORONARY ARTERY DISEASE; GENE THERAPY; HUMANS; MODELS, THEORETICAL; PERIPHERAL ARTERIAL DISEASE; SYSTEMS BIOLOGY;

DNA VIRUSES;

EID: 77957734075     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Auffray C, Chen Z, Hood L: Systems medicine: The future of medical genomics and healthcare. Genome Med (2009) 1 (1):2.
2. Ahn AC, Tewari M, Poon CS, Phillips RS: The clinical applications of a systems approach. PLoS Med (2006) 3(7):e209.
3. Ramsey SA, Gold ES, Aderem A: A systems biology approach to understanding atherosclerosis. EMBO Mol Med (2010) 2 (3):79-89.
4. Sefcik LS, Wilson JL, Papin JA, Botchwey EA: Harnessing systems biology approaches to engineer functional microvascular networks. Tissue Eng Part B Rev (2010) 16 (3):361-370. • Provides an excellent review of experimental datasets and predictive analysis in systems biology.
5. Popel AS, Hunter PJ: Systems biology and physiome projects. WIREs Systems Biology and Medicine (2009) 1 (2):153-158.
6. Mac Gabhann F, Popel AS: Systems biology of vascular endothelial growth factors. Microcirculation (2008) 15 (8):715-738.
7. Mac Gabhann F, Qutub AA, Annex BH, Popel AS: Systems biology of pro-angiogenic therapies targeting the VEGF system. WIREs Systems Biology Medicine (2010): doi:10.1002/wsbm.92.
8. Qutub AA, Liu G, Vempati P, Popel AS: Integration of angiogenesis modules at multiple scales: From molecular to tissue. Pac Symp Biocomput (2009):316-327.
9. Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS: Multiscale models of angiogenesis. IEEE Eng Med Biol Mag (2009) 28 (2):14-31.
10. Lowenstein PR, Castro MG: Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 9 (5):368-374. •• Describes an analysis of the failure of phase III clinical trials, demonstrating the value of computational models and systems biology in the translation of gene therapy from preclinical studies to trials.
11. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW: Decreased vascular repair and neovascularization with ageing: Mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Curr Mol Med (2008) 8 (8):754-767.
12. Hoenig MR, Bianchi C, Sellke FW: Hypoxia inducible factor-1α, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: A unifying hypothesis. Curr Drug Targets (2008) 9 (5):422-435.
13. Castro MG, Lowenstein PR: Gene therapy continues to make progress: Clinical and regulatory perspectives. Curr Gene Ther (2009) 9 (5):327-328.
14. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Faber K et al: Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med (2009) 15 (12):1431-1436. • Describes a novel method for the improved identification of viral integration sites in the human genome following retroviral gene delivery.
15. Felice B, Cattoglio C, Cittaro D, Testa A, Miccio A, Ferrari G, Luzi L, Recchia A, Mavilio F: Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One (2009) 4(2):e4571. • Describes a bioinformatic analysis that reveals motifs, particularly transcription factor-binding sites, for predicting retroviral integration sites.
16. Ferreira AJ, Raizada MK: Genomic and proteomic approaches for targeting of angiotensin-converting enzyme2 for cardiovascular diseases. Curr Opin Cardiol (2008) 23 (4):364-369.
17. Al-Humadi H, Zarros A, Al-Saigh R, Liapi C: Genetic basis and gene therapy trials for thyroid cancer. Cancer Genomics Proteomics (2010) 7 (1):31-49.
18. Abkowitz JL, Catlin SN, Guttorp P: Strategies for hematopoietic stem cell gene therapy: Insights from computer simulation studies. Blood (1997) 89 (9):3192-3198.
19. Abkowitz JL, Golinelli D, Guttorp P: Strategies to expand transduced hematopoietic stem cells in vivo. Mol Ther (2004) 9 (4):566-576.
20. Parra-Guillen ZP, Gonzalez-Aseguinolaza G, Berraondo P, Troconiz IF: Gene therapy: A pharmacokinetic/pharmacodynamic modelling overview. Pharm Res (2010) 27 (8):1487-1497. •• Provides an excellent review of both pharmacokinetic and pharmacodynamic models for simulating gene therapy.
21. Tayi VS, Bowen BD, Piret JM: Mathematical model of the rate-limiting steps for retrovirus-mediated gene transfer into mammalian cells. Biotechnol Bioeng (2010) 105 (1):195-209. •• Describes a computational model of the multiple steps in retroviral delivery, including cell surface binding, entry, reverse transcription, nuclear import and integration.
22. Lagache T, Dauty E, Holcman D: Physical principles and models describing intracellular virus particle dynamics. Curr Opin Microbiol (2009) 12 (4):439-445.
23. Schwake G, Youssef S, Kuhr JT, Gude S, David MP, Mendoza E, Frey E, Radler JO: Predictive modeling of non-viral gene transfer. Biotechnol Bioeng (2010) 105 (4):805-813. •• Describes a combined computational- experimental approach demonstrating that a two-step stochastic model best describes the transfection and co-transfection rates of plasmids.
24. Dinh AT, Pangarkar C, Theofanous T, Mitragotri S: Understanding intracellular transport processes pertinent to synthetic gene delivery via stochastic simulations and sensitivity analyses. Biophysical J (2007) 92 (3):831-846. • Describes a computational model of gene delivery using polymeric approaches that take into account cell geometry and endosomal trafficking.
25. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS: VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: An in silico model. Am J Physiol Heart Circ Physiol (2010) 298 (6):H2174-H2191.
26. Cooke EJ, Savage RS, Wild DL: Computational approaches to the integration of gene expression, ChIP-chip and sequence data in the inference of gene regulatory networks. Semin Cell Dev Biol (2009) 20 (7):863-868.
27. Niepel M, Spencer SL, Sorger PK: Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol (2009) 13 (5-6): 556-561.
28. Billy F, Ribba B, Saut O, Morre-Trouilhet H, Colin T, Bresch D, Boissel JP, Grenier E, Flandrois JP: A pharmacologically based multiscale mathematical model of angiogenesis and its use in investigating the efficacy of a new cancer treatment strategy. J Theor Biol (2009) 260 (4):545-562.
29. Berraondo P, Gonzalez-Aseguinolaza G, Troconiz IF: Semimechanistic pharmacodynamic modelling of gene expression and silencing processes. Eur J Pharm Sci (2009) 37 (3-4): 418-426. •• Discusses a mathematical model of the gene products that best describe gene silencing following the codelivering of reporter and expression plasmids.
30. Mac Gabhann F, Ji JW, Popel AS: Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann Biomed Eng (2007) 35 (6):982-994.
31. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH: Results of a doubleblind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 118 (1):58-65.
32. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation (2003) 108 (16):1933-1938.
33. Korpisalo P, Yla-Herttuala S: Stimulation of functional vessel growth by gene therapy. Integr Biol (Camb) (2010) 2 (2-3): 102-112.
34. Peirce SM: Computational and mathematical modeling of angiogenesis. Microcirculation (2008) 15 (8):739-751.
35. Byrne HM: Dissecting cancer through mathematics: From the cell to the animal model. Nat Rev Cancer (2010) 10 (3):221-230.
36. Gupta R, Tongers J, Losordo DW: Human studies of angiogenic gene therapy. Circulation Res (2009) 105 (8):724-736. •• Provides a comprehensive review of pro-angiogenic gene therapy applications in ischemic diseases, including coronary artery disease and peripheral artery disease.
37. Petrovic D: The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease. Cardiovasc Hematol Agents Med Chem (2010) 8 (1):47-54.
38. Yla-Herttuala S: Gene therapy with vascular endothelial growth factors. Biochem Soc Trans (2009) 37 (Pt 6):1198-1200.
39. Karvinen H, Yla-Herttuala S: New aspects in vascular gene therapy. Curr Opin Pharmacol (2010) 10 (2):208-211.
40. De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C: Meta-analysis of randomized, controlled clinical trials in angiogenesis: Gene and cell therapy in peripheral arterial disease. Heart Vessels (2009) 24 (5):321-328.
41. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M et al: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther (2008) 16 (5):972-978.
42. Samaranayake H, Maatta AM, Pikkarainen J, Yla-Herttuala S: Future prospects and challenges of antiangiogenic cancer gene therapy. Hum Gene Ther (2010) 21 (4):381-396. •• Provides a comprehensive review of the application of anti-angiogenic gene therapy for cancer.
43. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH et al: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature (2008) 451 (7181):1008-1012.
44. Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, Sawada N, Raghuram S, Arany Z: The transcriptional coactivator PGC-1α mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci USA (2009) 106 (50):21401-21406.
45. Ji JW, Mac Gabhann F, Popel AS: Skeletal muscle VEGF gradients in peripheral arterial disease: Simulations of rest and exercise. Am J Physiol Heart Circ Physiol (2007) 293 (6):H3740-H3749.
46. Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, Bianchi C, Sellke FW: Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol (2009) 296 (2):H428-H434.
47. Sodha NR, Boodhwani M, Clements RT, Xu SH, Khabbaz KR, Sellke FW: Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients. Arch Surg (2008) 143 (5):463-470.
48. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH: Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: Differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res (2007) 101 (9):948-956.
49. Roncalli J, Tongers J, Renault MA, Losordo DW: Biological approaches to ischemic tissue repair: Gene-and cell-based strategies. Expert Rev Cardiovasc Ther (2008) 6 (5):653-668.
50. Tongers J, Roncalli JG, Losordo DW: Therapeutic angiogenesis for critical limb ischemia: Microvascular therapies coming of age. Circulation (2008) 118 (1):9-16.
51. Misteli H, Wolff T, Fuglistaler P, Gianni-Barrera R, Gurke L, Heberer M, Banfi A: High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo. Stem Cells (2010) 28 (3):611-619.
52. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM: Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest (2004) 113 (4):516-527.
53. Mac Gabhann F, Peirce SM: Collateral capillary arterialization following arteriolar ligation in murine skeletal muscle. Microcirculation (2010) 17 (5):333-347.
54. Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB, Wakhloo AK, Webster KA: Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther (2005) 12 (9):762-771.
55. Boodhwani M, Voisine P, Ruel M, Sodha NR, Feng J, Xu SH, Bianchi C, Sellke FW: Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction. Eur J Cardiothorac Surg (2008) 33 (4):645-650; discussion 251-252.
56. Boodhwani M, Mieno S, Feng J, Sodha NR, Clements RT, Xu SH, Sellke FW: Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. J Thoracic Cardiovasc Surg (2008) 135 (1):117-122.
57. Boodhwani M, Mieno S, Voisine P, Feng J, Sodha N, Li J, Sellke FW: High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. J Thoracic Cardiovasc Surg (2006) 132 (6):1299-1306. (Pubitemid 44820192)
58. Kaur S, Kumar TR, Uruno A, Sugawara A, Jayakumar K, Kartha CC: Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: An in vitro study. Basic Res Cardiol (2009) 104 (6):739-749.
59. Tongers J, Roncalli JG, Losordo DW: Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvascular Res (2010) 79 (3):200-206.
60. Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG: Gene therapy for brain cancer: Combination therapies provide enhanced efficacy and safety. Curr Gene Ther (2009) 9 (5):409-421.
61. Benest AV, Stone OA, Miller WH, Glover CP, Uney JB, Baker AH, Harper SJ, Bates DO: Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol (2008) 28 (8):1462-1468.
62. Li J, Wei Y, Liu K, Yuan C, Tang Y, Quan Q, Chen P, Wang W, Hu H, Yang L: Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc Res (2010) 80 (1):10-17.
63. Matyas L, Schulte KL, Dormandy JA, Norgren L, Sowade O, Grotzbach G, Palmer-Kazen U, Rubanyi GM, Wahlberg E: Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: A randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther (2005) 16 (10):1202-1211.
64. de Paula EV, Flores-Nascimento MC, Arruda VR, Garcia RA, Ramos CD, Guillaumon AT, Annichino-Bizzacchi JM: Dual gene transfer of fibroblast growth factor-2 and platelet derived growth factor-BB using plasmid deoxyribonucleic acid promotes effective angiogenesis and arteriogenesis in a rodent model of hindlimb ischemia. Transl Res (2009) 153 (5):232-239.
65. Kitsios G, Zintzaras E: ACE (I/D) polymorphism and response to treatment in coronary artery disease: A comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet (2009) 10:50.
66. Petrovic D: Vascular endothelial growth factor gene polymorphisms and myocardial infarction. Cardiology (2009) 114 (1):8-10.
67. Boodhwani M, Sellke FW: Therapeutic angiogenesis in diabetes and hypercholesterolemia: Influence of oxidative stress. Antiox Redox Signal (2009) 11 (8):1945-1959.